BE2015C066I2 - - Google Patents

Download PDF

Info

Publication number
BE2015C066I2
BE2015C066I2 BE2015C066C BE2015C066C BE2015C066I2 BE 2015C066 I2 BE2015C066 I2 BE 2015C066I2 BE 2015C066 C BE2015C066 C BE 2015C066C BE 2015C066 C BE2015C066 C BE 2015C066C BE 2015C066 I2 BE2015C066 I2 BE 2015C066I2
Authority
BE
Belgium
Application number
BE2015C066C
Other languages
Dutch (nl)
Original Assignee
Merck Sharp & Dohme Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme Llc filed Critical Merck Sharp & Dohme Llc
Publication of BE2015C066I2 publication Critical patent/BE2015C066I2/nl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01DNA viruses
    • C07K14/025Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04Inactivation or attenuation; Producing viral sub-units
    • C12N7/045Pseudoviral particles; Non infectious pseudovirions, e.g. genetically engineered
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5258Virus-like particles
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/20011Papillomaviridae
    • C12N2710/20022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/20011Papillomaviridae
    • C12N2710/20023Virus like particles [VLP]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BE2015C066C 2004-03-24 2015-12-09 BE2015C066I2 (lt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US55592604P 2004-03-24 2004-03-24

Publications (1)

Publication Number Publication Date
BE2015C066I2 true BE2015C066I2 (lt) 2024-08-08

Family

ID=34964085

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2015C066C BE2015C066I2 (lt) 2004-03-24 2015-12-09

Country Status (31)

Country Link
US (2) US7700103B2 (lt)
EP (1) EP1730175B1 (lt)
JP (1) JP4833962B2 (lt)
KR (1) KR101203403B1 (lt)
CN (1) CN1934131B (lt)
AR (1) AR048191A1 (lt)
AT (1) ATE466022T1 (lt)
AU (1) AU2005230907C1 (lt)
BE (1) BE2015C066I2 (lt)
BR (1) BRPI0509079B8 (lt)
CA (1) CA2560487C (lt)
CY (2) CY1110349T1 (lt)
DE (1) DE602005020913D1 (lt)
DK (1) DK1730175T3 (lt)
ES (1) ES2343255T3 (lt)
FR (1) FR15C0085I2 (lt)
HU (1) HUS1500062I1 (lt)
IL (1) IL178140A (lt)
LT (2) LTPA2015050I1 (lt)
LU (1) LU92903I2 (lt)
MY (1) MY148656A (lt)
NL (1) NL300777I1 (lt)
NO (3) NO338055B1 (lt)
NZ (1) NZ549898A (lt)
PL (1) PL1730175T3 (lt)
PT (1) PT1730175E (lt)
RU (1) RU2373219C2 (lt)
SI (1) SI1730175T1 (lt)
TW (1) TWI349036B (lt)
WO (1) WO2005097821A1 (lt)
ZA (1) ZA200607575B (lt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7858098B2 (en) * 2002-12-20 2010-12-28 Glaxosmithkline Biologicals, S.A. Vaccine
CN1869215B (zh) * 2006-05-19 2012-07-04 长春百克生物科技股份公司 一种制备人乳头瘤病毒的病毒样颗粒的方法
WO2008112125A1 (en) 2007-03-09 2008-09-18 Merck & Co., Inc. Papillomavirus vaccine compositions
EP2223933B1 (en) 2007-11-23 2016-01-27 Shanghai Zerun Biotechnology Co., Ltd. Genes encoding major capsid protein l1 of human papilloma viruses
CN101440371B (zh) * 2007-11-23 2012-09-05 上海泽润生物科技有限公司 一种16型人乳头状瘤病毒主要衣壳蛋白l1基因
KR102085465B1 (ko) * 2010-05-14 2020-03-05 박스알타 인코퍼레이티드 키메라 ospa 유전자, 단백질 및 이의 사용 방법
JP6153866B2 (ja) 2010-05-25 2017-06-28 キアゲン ガイサーズバーグ アイエヌシー. 迅速なハイブリッド捕捉アッセイ、及び関連する戦略的に切断されたプローブ
DK2589604T3 (en) 2010-07-02 2017-01-16 Univ Xiamen TRUNCATED L1 PROTEIN OF HUMAN PAPILLOMAVIRUS TYPE 52
US8361720B2 (en) * 2010-11-15 2013-01-29 Exact Sciences Corporation Real time cleavage assay
US9018451B2 (en) 2010-12-03 2015-04-28 M S Technologies, LLC Optimized expression of glyphosate resistance encoding nucleic acid molecules in plant cells
CN102154325B (zh) * 2011-01-01 2013-08-21 上海生物制品研究所有限责任公司 针对人乳头瘤状病毒的疫苗及其制法和用途
RU2445358C1 (ru) * 2011-02-15 2012-03-20 Закрытое акционерное общество научно-производственная компания "Комбиотех" Рекомбинантный штамм дрожжей pichia angusta - продуцент капсидного белка l1 вируса папилломы человека типа 18
RU2445357C1 (ru) * 2011-02-15 2012-03-20 Закрытое акционерное общество научно-производственная компания "Комбиотех" Рекомбинантный штамм дрожжей pichia angusta - продуцент капсидного белка l1 вируса папилломы человека типа 16
CN110484554B (zh) * 2013-04-26 2024-04-16 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv52 l1蛋白的方法
CN110592133A (zh) * 2013-05-17 2019-12-20 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv31 l1蛋白的方法
WO2015057541A1 (en) 2013-10-16 2015-04-23 Merck Sharp & Dohme Corp. Method of obtaining thermostable dried vaccine formulations
CN104878022A (zh) * 2015-04-27 2015-09-02 段青姣 编码hpv58l1、hpv52l1蛋白的核苷酸序列及其应用
CN106701796B (zh) * 2015-08-12 2021-11-16 北京康乐卫士生物技术股份有限公司 52型重组人乳头瘤病毒病毒样颗粒及其制备方法
CN109750049B (zh) * 2017-11-07 2023-08-18 上海泽润生物科技有限公司 重组人乳头瘤病毒52亚型蛋白表达
MX2022009964A (es) 2020-02-14 2022-09-19 Merck Sharp & Dohme Llc Vacuna contra hpv.
CN114539365B (zh) * 2020-11-26 2023-12-01 中国医学科学院基础医学研究所 一种改造的人乳头瘤病毒52型l1蛋白及其用途
CN113073105B (zh) * 2021-03-23 2023-06-13 重庆博唯佰泰生物制药有限公司 一种表达hpv 56l1的多核苷酸序列及其表达载体、宿主细胞和应用
CN113549634B (zh) * 2021-06-07 2023-03-31 郑州大学 编码可溶性hpv58 l1蛋白的基因及其重组质粒的构建与应用
TW202313658A (zh) 2021-08-06 2023-04-01 美商默沙東有限責任公司 Hpv疫苗
MX2024002144A (es) 2021-08-19 2024-04-23 Merck Sharp & Dohme Llc Nueva nanoparticula lipidica termostable y metodos de uso de la misma.

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1339729C (en) * 1988-10-26 1998-03-17 Wayne D. Lancaster Human papillomavirus type 52 dna sequences and methods for employing thesame
US5821087A (en) 1995-03-30 1998-10-13 Merck & Co., Inc. Production of recombinant human papillomavirus type II protein utilizing papillomavirus 6/11 hybrid DNA
IL117591A0 (en) 1995-03-30 1996-07-23 Merck & Co Inc Synthetic DNA encoding human papillomavirus type 11 L1 protein
ATE342916T1 (de) 1997-02-07 2006-11-15 Merck & Co Inc Synthetische hiv gag gene
JP4434479B2 (ja) 1997-07-09 2010-03-17 ザ・ユニバーシティ・オブ・クイーンズランド 標的の細胞および組織においてタンパク質を選択的に発現するための核酸配列および方法
PL347472A1 (en) * 1998-08-14 2002-04-08 Merck & Co Inc Process for purifying human papillomavirus virus-like particles
DE69933875T2 (de) 1998-08-14 2007-05-31 Merck & Co., Inc. Protein-verabreichungssystem, das dem menschlichen papillomavirus ähnliche partikel benützt.
SE514982C2 (sv) * 1999-09-30 2001-05-28 Active Biotech Ab Bärare innehållande ett huvudkapsidprotein L1 från humant papillomavirus samt dess användning
CA2381991A1 (en) * 1999-08-25 2001-03-01 Merck & Co., Inc. Synthetic human papillomavirus genes
US6436402B1 (en) 1999-10-15 2002-08-20 Merck & Co., Inc. Process for making human papillomavirus virus-like particles with improved properties
DE60124918T2 (de) 2000-07-21 2007-08-02 Glaxo Group Ltd., Greenford Kodon-optimierte papillomavirussequenzen
US20030226155A1 (en) * 2001-08-30 2003-12-04 Biorexis Pharmaceutical Corporation Modified transferrin-antibody fusion proteins
BRPI0408639B8 (pt) 2003-03-24 2021-05-25 Merck Sharp & Dohme molécula de ácido nucleico, vetor, célula hospedeira de levedura e método para produzir partículas semelhantes a vírus de hpv31
MY140664A (en) * 2003-09-29 2010-01-15 Merck Sharp & Dohme Optimized expression of hpv 45 l1 in yeast
MY139500A (en) 2003-11-12 2009-10-30 Merck Sharp & Dohme Optimized expression of hpv 58 l1 in yeast

Also Published As

Publication number Publication date
CN1934131A (zh) 2007-03-21
JP4833962B2 (ja) 2011-12-07
FR15C0085I2 (fr) 2016-11-25
IL178140A0 (en) 2006-12-31
CY2015052I1 (el) 2016-06-22
US20100035818A1 (en) 2010-02-11
HUS1500062I1 (hu) 2017-07-28
RU2006137363A (ru) 2008-04-27
PL1730175T3 (pl) 2010-09-30
NZ549898A (en) 2009-06-26
WO2005097821A1 (en) 2005-10-20
BRPI0509079B8 (pt) 2021-07-06
PT1730175E (pt) 2010-06-25
LTPA2015050I1 (lt) 2016-01-11
BRPI0509079A (pt) 2007-08-21
MY148656A (en) 2013-05-15
RU2373219C2 (ru) 2009-11-20
AU2005230907C1 (en) 2016-07-28
DK1730175T3 (da) 2010-08-23
CY2015052I2 (el) 2016-06-22
TW200602490A (en) 2006-01-16
JP2007530040A (ja) 2007-11-01
US20080226660A1 (en) 2008-09-18
US7744892B2 (en) 2010-06-29
FR15C0085I1 (lt) 2016-08-01
AU2005230907A1 (en) 2005-10-20
KR101203403B1 (ko) 2012-11-21
CY1110349T1 (el) 2015-04-29
AU2005230907B2 (en) 2011-05-19
CA2560487C (en) 2013-01-29
NL300777I2 (lt) 2015-12-29
NL300777I1 (lt) 2015-12-29
US7700103B2 (en) 2010-04-20
BRPI0509079B1 (pt) 2020-05-19
LTC1730175I2 (lt) 2017-05-10
EP1730175A1 (en) 2006-12-13
NO2017005I1 (no) 2017-01-20
EP1730175B1 (en) 2010-04-28
NO2022050I1 (no) 2022-11-30
NO338055B1 (no) 2016-07-25
AR048191A1 (es) 2006-04-05
ZA200607575B (en) 2008-08-27
KR20060134120A (ko) 2006-12-27
NO20064815L (no) 2006-10-23
IL178140A (en) 2010-11-30
ATE466022T1 (de) 2010-05-15
DE602005020913D1 (de) 2010-06-10
CA2560487A1 (en) 2005-10-20
LU92903I2 (fr) 2016-03-08
ES2343255T3 (es) 2010-07-27
TWI349036B (en) 2011-09-21
SI1730175T1 (sl) 2010-08-31
CN1934131B (zh) 2010-12-29

Similar Documents

Publication Publication Date Title
BE2024C508I2 (lt)
BE2022C549I2 (lt)
BE2024C511I2 (lt)
BE2020C513I2 (lt)
BE2020C517I2 (lt)
BE2019C540I2 (lt)
BE2019C548I2 (lt)
BE2018C045I2 (lt)
BE2017C027I2 (lt)
BE2017C023I2 (lt)
BE2017C002I2 (lt)
BE2016C067I2 (lt)
BE2015C066I2 (lt)
BE2019C535I2 (lt)
JP2004332738A5 (lt)
BR122015024347A2 (lt)
JP2004254308A5 (lt)
BRPI0508002A (lt)
JP2005332130A5 (lt)
BE2016C042I2 (lt)
BE2015C033I2 (lt)
JP2004332731A5 (lt)
JP2004219423A5 (lt)
JP2005083375A5 (lt)
BE2015C035I2 (lt)